Discussion
SARS-COV-2 INFECTION
Our study provides timely real-world evidence of the comparative effectiveness of the BNT162b2 and the ChAdOx1 vaccines against the risk of SARS-CoV-2 infection. Individuals who received the BNT162b2 vaccine had a 30% lower risk of SARS-CoV-2 infection than those who received the ChAdOx1 vaccine over 10 months of follow-up. Our findings are consistent across sex, age, and study periods and unlikely to be explained by major residual confounders. In addition, the BNT162b2 vaccine appears to provide a better protective effect on hospitalisation for COVID-19 than the ChAdOx1 vaccine.